Ungerechts Lab

Guy Ungerechts profile picture

Contact Information

Guy Ungerechts, MD, PhD


Ottawa Hospital Research Institute
Center for Cancer Therapeutics
501 Smyth Rd. Box 926,
Ottawa, On, K1H 8L6

Guy Ungerechts

Affiliate Investigator, Cancer Therapeutics Program
Ottawa Hospital Research Institute
Head of the Research Group “Virotherapy”, Center for Cancer Therapeutics
Ottawa Hospital Research Institute
Assistant Professor, Faculty of Medicine
University of Ottawa
Deputy Director, Medical Oncology
Heidelberg University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany
CanVirex (Spin-Off Company for Oncolytic Viruses)
Attending Physician (2015-2017), Medical Oncology
The Ottawa Hospital

Research Interests

Dr. Ungerechts’ interests lie in the field of immunovirotherapy, based on recombinant oncolytic viruses including Measles virus.
As a Clinician Scientist, Dr. Ungerechts and his team have contributed significantly to the pre-clinical development of next-generation oncolytic viruses and also their translation from bench-to-bedside in several phase I/II and III clinical trials.

Brief Biography

Guy Ungerechts MD, PhD, is a medical oncologist trained in the field of oncolytic viruses at Mayo Clinic, Rochester, USA and at the Ottawa Hospital Research Institute (OHRI), Ottawa, Canada. As a staff medical oncologist, he was a member of the GI cancer group at The Ottawa Hospital (TOH) between 2015 and 2017. Currently, he is an Assistant Professor at the University of Ottawa and PI/Affiliated Investigator at the OHRI in the Cancer Therapeutics Program. He also is the Deputy Director of the Medical Oncology Department at the University Hospital and National Center for Tumor Diseases (NCT), Heidelberg, Germany. His clinical focus is GI oncology with particular interests in translational medicine and early clinical trials of immuno(viro)therapy.

Since 2008 Dr. Ungerechts has been head of the Virotherapy group at NCT/German Cancer Research Center as an independent investigator and coordinates the German Virotherapy Consortium. He has been responsible for the development and conduction of several Phase I/II and III trials with oncolytic viruses derived from different platforms including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T cell engager (BITEs) for enhanced immunovirotherapy.

In 2015 he received the Ontario Institute for Cancer Research (OICR) Investigator Award for Clinician Scientists and in 2016 the Terry Fox New Investigator Award.

Selected Publications

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE.
Clin Cancer Res. 2018 May 1;24(9):2128-2137. 

Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.
Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfeld C, Jäger D, von Kalle C, Ungerechts G.
Mol Ther Oncolytics. 2018 Apr 12;9:30-40.

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.
Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE.
Oncoimmunology. 2017 Jan 31;6(4):e1285992.

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy.
Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G.
Mol Ther. 2014 Nov;22(11):1949-59.

GM-CSF-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
Hum Gene Ther. 2013 Jul;24(7):644-54.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.
J Invest Dermatol. 2013 Apr;133(4):1034-42. 

Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.
Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G.
Cancer Gene Ther. 2011 Aug;18(8):598-608.

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G.
Mol Ther. 2011 Jun;19(6):1097-106.

Diseases, conditions and populations of interest

Research and clinical approaches